September 6, 2011 – Hawthorn Pharmaceuticals, Inc. announced an exclusive global licensing deal with CoPlex Therapeutics on hawAD14, a preclinical oral small molecule candidate for the treatment of Alzheimer's and other neurodegenerative diseases.
Under the terms of the agreement, Hawthorn will receive an exclusive worldwide license to develop and commercialize hawAD14 and will be responsible for funding all future development.
Research indicates hawAD14 significantly decreases levels of Amyloid Beta (Aß) and tau phosphorylation activity, the main constituents of amyloid plaques and paired helical filaments that make up neurofibrillary tangles in Alzheimer's disease... Hawthorn Pharmaceuticals' Press Release -
